Procter and Gamble, Central Product Safety, Mason, OH, USA.
Procter and Gamble, Central Product Safety, Brussels, Belgium.
Regul Toxicol Pharmacol. 2018 Nov;99:116-121. doi: 10.1016/j.yrtph.2018.09.011. Epub 2018 Sep 18.
When evaluating consumer products for safety, one must consider the heterogeneity of the population that might use those products, including the potential for different sensitivity based on factors such as age, gender, and genetics. For both systemic endpoints and allergic contact dermatitis (ACD), quantitative safety evaluations typically include a default 10-fold uncertainty/assessment factor to account for inter-individual variability. While this factor is intended to include age, the adequacy of the default 10-fold factor has been questioned for infants, for whom a precautionary assumption is often made that they are more sensitive. In-depth evaluations of the adequacy of the 10-fold factor have been published for systemic endpoints, but relatively little has been published to substantiate this for ACD. This paper reviews the state of the science regarding the etiology of ACD and factors that suggest an overall decreased sensitivity associated with early life exposures, thus confirming the sufficiency of the 10-fold inter-individual factor to provide protection for children and infants. While it remains prudent for all age groups to avoid contact with sensitizers, it is concluded that the quantitative methods used in safety evaluation to prevent the induction of skin sensitization are protective for infants, including neonates and premature infants.
在评估消费品的安全性时,必须考虑到可能使用这些产品的人群的异质性,包括基于年龄、性别和遗传等因素的潜在不同敏感性。对于系统性终点和过敏性接触性皮炎 (ACD),定量安全性评估通常包括默认的 10 倍不确定性/评估因素,以考虑个体间的变异性。虽然该因素旨在包括年龄,但对于婴儿,该默认的 10 倍因素是否足够一直存在疑问,因为通常会假设婴儿更敏感。已经发表了关于系统性终点 10 倍因素充分性的深入评估,但相对较少的研究证实了这一点对于 ACD。本文综述了 ACD 的病因学以及提示与生命早期暴露相关的整体敏感性降低的因素,从而证实了 10 倍个体间因素足以保护儿童和婴儿。虽然对于所有年龄段的人来说,避免接触敏化剂仍然是谨慎的,但结论是,用于预防皮肤致敏的安全性评估中的定量方法对婴儿(包括新生儿和早产儿)具有保护作用。